Dawson James Small Cap Growth Conference
October 28-29, 2019
Jupiter, Florida
The fifth annual Dawson James Small Cap Growth Conference features two days of presentations from more than 30 companies in the health care, technology and consumer sectors. Last year's event was attended by more than 300 of Dawson James' institutional, family office and high net worth clients. For more information visit www.DawsonJames.com
Presenting Companies
AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc. (NYSE: AIM) is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. The company's flagship products include the Argentina-approved drug rintatolimod (Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system. For more information, visit the company's website at www.aimimmuno.com.
Artelo Biosciences Inc. (ARTL)
Artelo Biosciences (NASDAQ: ARTL) is applying exacting biopharma discipline toward developing and commercializing a diverse portfolio of novel therapeutic candidates targeting the endocannabinoid system. By leveraging past research and leading-edge, world-class science, Artelo is rapidly advancing a portfolio of endocannabinoid system modulating therapeutics. The company's broadly applicable product candidates have the potential to dramatically improve patient care in multiple major markets. Artelo expects to deliver on the promise of new therapeutic medicines to treat a wide range of diseases and conditions, creating value for patients, the medical community and investors. For more information, visit the company's website at www.artelobio.com.
Athersys Inc. (ATHX)
Athersys (NASDAQ: ATHX) is working to change the future of medicine. A clinical-stage biotechnology company, Athersys is developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. With a focus on developing therapies in regenerative medicine, Athersys is developing therapeutic products the company believes have best-in-class potential. The company's lead platform product, MultiStem cell therapy, has shown promise for treating indications in the neurological, inflammatory and immune, and cardiovascular disease areas. Its most advanced program focused on the treatment of ischemic stroke is in a phase 3 clinical trial. Athersys' wide ranging clinical development programs represent major areas of clinical need, as well as substantial commercial opportunities. For more information, visit the company's website at www.athersys.com.
Atossa Genetics Inc. (ATOS)
Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. Atossa is developing "endoxifen" to mitigate breast cancer risk by reducing the density of breast tissue; to reduce the cancer cell activity before surgery; and to reduce the risk of recurrent or new breast cancer after the initial treatment. The company is also developing a new way to deliver therapies, such as "CAR-T" cells, through microcatheters directly to the site of breast cancer. The company believes its innovative therapies and delivery methods can transform breast cancer treatment and improve outcomes. For more information, visit the company's website at www.atossagenetics.com.
AzurRx BioPharma Inc. (AZRX)
AzurRx BioPharma (NASDAQ: AZRX) is a business-led, science-driven, and clinically advanced development-stage biopharmaceutical company. AzurRx BioPharma is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. The company's lead development program, MS1819, is a recombinant lipase for the treatment of exocrine pancreatic insufficiency indicated for cystic fibrosis and chronic pancreatitis patients. AZX1103 is a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. AzurRx BioPharma's core technologies of next-generation enzymes are novel, advanced therapeutic and represent the next forward in the fight to treat diseases that impact daily life and the ability to thrive. For more information, visit the company's website at www.azurrx.com.
BeyondSpring Inc. (BYSI)
BeyondSpring (NASDAQ: BYSI) is a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring employs a novel, scalable business model that integrates U.S. and Chinese clinical resources, aimed at creating maximum value for all stakeholders. BeyondSpring also intends to pursue internal development and selective acquisitions of pharmaceutical products with a clear, near-term pathway to global approvals. BeyondSpring has a robust drug development pipeline at various clinical and pre-clinical stages. The company's lead asset, Plinabulin, is in a phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two phase 3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). For more information, visit the company's website at www.beyondspringpharma.com.
BioCardia (BCDA)
BioCardia (NASDAQ: BCDA) is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP™ and CardiALLO™ cell therapies are the company's biotherapeutic product candidates in clinical development. BioCardia's current products include the Helix™ Biotherapeutic Delivery System and the Morph® steerable guide and sheath catheter portfolio, including the new AVANCE™ Steerable Introducer family. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit the company's website at www.biocardia.com.
BrainStorm Cell Therapeutics Inc. (BCLI)
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases such as ALS, Multiple Sclerosis and Parkinson's Disease. BrainStorm holds the exclusive worldwide rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. FDA and the European Medicines Agency in ALS. BrainStorm is currently enrolling a phase 3 pivotal trial in ALS, investigating repeat-administration of autologous MSC-NTF cells. The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. For more information, visit the company's website at www.brainstorm-cell.com.
Caladrius Biosciences (CLBS)
Caladrius Biosciences (NASDAQ: CLBS) is a clinical-stage biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses. Caladrius currently has four programs in the mid to late stages of clinical development. The company's product candidates include three cell therapies for cardiovascular diseases that are based on its autologous CD34+ cell therapy platform, two in phase 2 testing and one in late-stage development. In addition, Caladrius has an autoimmune product candidate, CLBS03, also in phase 2 testing. Caladrius' goal is to build a broad portfolio of novel and versatile products that address important unmet medical needs. For more information, visit the company's website at www.caladrius.com.
Can-Fite Biopharma Ltd. (CANF)
Can-Fite BioPharma (NYSE: CANF) is an advanced clinical-stage drug development company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancers. Can-Fite's technology platform is based on the finding that the Gi protein coupled A3 adenosine receptor (A3AR) is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells. The company has several drugs in various stages of research and development. Its lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. For more information, visit the company's website at www.can-fite.com.
CEL-SCI Corp. (CVM)
CEL-SCI (NYSE: CVM) is at the forefront in the research and development of products for the treatment of cancer, autoimmune and infectious diseases. CEL-SCI believes that boosting a patient's immune system while still intact should provide the greatest possible impact on survival. The company's core capabilities include drug discovery, research, development and manufacturing of complex biological substances. CEL-SCI's phase 3 study is the largest phase 3 study in the world for the treatment of head and neck cancer, and after 8.5 years is very close to completion. Multikine, CEL-SCI's lead investigational therapy, is a potential therapeutic agent directed at enabling the immune system to use the body's own anti-tumor immune response. For more information, visit the company's website at www.cel-sci.com.
Celsion Corp. (CLSN)
Celsion (NASDAQ: CLSN) is a fully integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. Celsion's mission is to transform the landscape of cancer treatment with novel targeting technologies. The company's lead product candidate is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a phase 3 trial combined with RFA for the treatment of hepatocellular carcinoma. Second in Celsion's pipeline is GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian cancer. Celsion has 3 platform technologies providing the basis for the development of a range of therapeutics for difficult-to-treat forms of cancers. For more information, visit the company's website at www.celsion.com.
Cesca Therapeutics Inc. (KOOL)
Cesca Therapeutics (NASDAQ: KOOL) develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Cesca's device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The company's clinical development division leverages its proprietary AutoXpress technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the immuno-oncology, vascular, cardiology and orthopedic markets. For more information, visit the company's website at www.cescatherapeutics.com.
Check-Cap Ltd. (CHEK)
Check-Cap (NASDAQ: CHEK) (NASDAQ: CHEKW) (NASDAQ: CHEKZ) is advancing the development of the C-Scan® System, the first and only preparation-free ingestible scanning capsule-based system for the prevention of colorectal cancer ("CRC") through the detection of precancerous polyps. The patient-friendly test has the potential to increase screening adherence and reduce the overall incidence of CRC. The C-Scan® System utilizes an ultra-low dose X-ray capsule, an integrated positioning, control, and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon. The C-Scan® System is non-invasive and requires no preparation or sedation, allowing patients to continue their daily routine with no interruption as the capsule is propelled through the gastrointestinal tract by natural motility. For more information, visit the company's website at www.check-cap.com.
Citius Pharmaceuticals Inc. (CTXR)
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is a specialty pharmaceutical company focused on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously approved pharmaceutical ingredients. By using previously approved drugs with substantial safety and efficacy data, the company seeks to reduce risks associated with pharmaceutical product development and regulatory requirements. The company develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. Citius intends to achieve leading market positions by providing therapeutic products that address unmet medical needs. For more information, visit the company's website at www.citiuspharma.com.
CollPlant (CLGN)
CollPlant (NASDAQ: CLGN) is focused on 3D bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics and advanced wound care markets. The company's products are based on its rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology. CollPlant's products address indications for the diverse fields of organ and tissue repair. The company's flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. Last year, CollPlant entered into a licensing agreement with United Therapeutics, and United Therapeutics is now using BioInks in the manufacture of 3D bioprinted lungs for transplant in humans. For more information, visit the company's website at www.collplant.com.
Dare Bioscience Inc. (DARE)
Dare Bioscience (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's sexual health, vaginal health, fertility and contraception. The company is identifying, developing and bringing to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women's health. Dare's product portfolio includes potential first-in-class candidates in clinical development: Ovaprene, a non-hormonal, monthly contraceptive vaginal ring; and Sildenafil Cream, a potential treatment for female sexual arousal disorder, as well as a proprietary solution-to-gel formulation of clindamycin to treat bacterial vaginosis via a single application. For more information, visit the company's website at www.darebioscience.com.
DelMar Pharmaceuticals Inc. (DMPI)
DelMar Pharmaceuticals (NASDAQ: DMPI) concentrates on the development and commercialization of new therapies for cancer patients who have limited or no treatment options. Focused on understanding tumor biology and mechanisms of treatment resistance, DelMar identifies biomarkers to personalize new therapies in indications where patients are failing, or are unable to tolerate, standard-of-care treatments. The company's current pipeline is based around VAL-083, a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including central nervous system, ovarian and other solid tumors in U.S. clinical trials sponsored by the NCI. Delmar is conducting clinical trials to support the development and commercialization of VAL-083 to solve significant unmet medical needs. For more information, visit the company's website at www.delmarpharma.com.
Dyadic International Inc. (DYAI)
Dyadic International (NASDAQ: DYAI) is a global biotechnology company developing a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large-scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is leveraging its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars, and other therapeutic proteins. For more information, visit the company's website at www.dyadic.com.
Fortress Biotech Inc. (FBIO)
Fortress Biotech (NASDAQ: FBIO) is an innovative biopharmaceutical company identifying, in-licensing and developing high-potential clinical-stage assets. The company has over 25 programs in clinical development at Fortress, at its majority-owned and majority-controlled subsidiaries, and at entities it founded and holds significant minority ownership positions. The product candidates span six large-market therapeutic areas, including oncology, rare diseases and gene therapy, which allow it to create value while mitigating risk for shareholders. The company advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity. For more information, visit the company's website at www.fortressbiotech.com.
Hoth Therapeutics Inc. (HOTH)
Hoth Therapeutics (NASDAQ: HOTH) is focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform for all indications in humans. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur. For more information, visit the company's website at www.hoththerapeutics.com.
IMAC Holdings Inc. (IMAC)
IMAC Holdings (NASDAQ: IMAC) combines life science advancements with traditional medical care for movement-restricting diseases and conditions. The company owns or manages outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. IMAC Regeneration Centers provide medical services for movement-restricting conditions. It has partnered with several active and former professional athletes, including brand ambassadors Ozzie Smith, David Price, Tony Delk and Mike Ditka. IMAC's outpatient medical clinics emphasize its focus around treating sports and orthopedic injuries without surgery or opioids. For more information, visit the company's website at www.imacregeneration.com.
Interpace Diagnostics Group Inc. (IDXG)
Interpace Diagnostics Group (NASDAQ: IDXG) is a fully integrated commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. A leader in enabling personalized medicine, Interspace offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The company's molecular diagnostic tests deliver cutting-edge genetic and mutational analysis that help risk-stratify patient samples for thyroid, pancreatic, lung and other cancers to better inform treatment decisions. Supported by rigorous science, the company's molecular diagnostic tests allow healthcare providers the ability to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients. For more information, visit the company's website at www.interpacediagnostics.com.
Lineage Cell Therapeutics Inc. (LCTX)
Lineage Cell Therapeutics (NYSE: LCTX) is a clinical-stage biotech company developing novel cell therapies for unmet medical needs. The company's programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. Utilizing its unique platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage is developing three cell therapy programs in various stages of clinical development. Lineage also has a cell delivery clinical program and investments in other public companies. For more information, visit the company's website at www.lineagecell.com.
Medexus Pharmaceuticals Inc. (TSXV: MDP) (PDDPF)
Medexus Pharmaceuticals (TSXV: MDP) (OTCQB: PDDPF) is a leading specialty pharmaceutical company with a strong North American commercial platform. The company's vision is to provide the best healthcare products to healthcare professionals and patients through the core values of quality, innovation, customer service and teamwork. Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics. The company's leading products are Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall™, an innovative allergy medication with a unique mode of action. For more information, visit the company's website at www.medexus.com.
Mesoblast Ltd. (MESO)
A global leader in cellular medicines for inflammatory diseases, Mesoblast (NASDAQ: MESO) is developing allogeneic (off-the-shelf) cellular medicines. Mesoblast leverages its proprietary technology platform to establish a broad portfolio of late-stage product candidates with three product candidates in phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses from each donor without the need for tissue matching. For more information, visit the company's website at www.mesoblast.com.
Orgenesis Inc. (ORGS)
Orgenesis (NASDAQ: ORGS) is a vertically integrated biopharmaceutical company specializing in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. Through its subsidiary, MaSTherCell, Orgenesis delivers optimized process industrialization capacities to cell therapy companies and speeds the arrival of these therapies to market. MaSTherCell's customers include many of the world's leading pharmaceutical and biotech companies, as well as research institutions and hospitals involved in cutting edge cell therapy. Orgenesis is also developing its own propriety cell therapies and is a pioneer in the process of trans-differentiation (cell reprograming). Orgenesis has utilized its proprietary technology/processes to successfully reprogram human liver cells into glucose-responsive, fully functional, insulin producing cells. For more information, visit the company's website at www.orgenesis.com.
Soligenix Inc. (SNGX)
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's specialized biotherapeutics segment is dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn's disease, acute radiation enteritis. The company's public health solutions segment develops vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, acute radiation syndrome, and emerging and antibiotic resistant infectious disease. Soligenix is developing multiple pipeline products with fast track and/or orphan designation, each of which holds potential for significant commercial returns. For more information, visit the company's website at www.soligenix.com.
Sophiris Bio Inc. (SPHS)
A late-stage, clinical biopharmaceutical company, Sophiris Bio (NASDAQ: SPHS) is developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin, a first-in-class, pore-forming protein, is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations around prostate tumor cells and in the transition zone of the prostate. Topsalysin has completed two phase 2 clinical trials for the focal treatment of localized prostate cancer as well as one Phase 3 clinical trial for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). More than 450 patients have received topsalysin, which continues to appear to be safe and well tolerated. For more information, visit the company's website at www.sophirisbio.com.
Todos Medical Ltd. (TOMDF)
Todos Medical Ltd. (OTCQB: TOMDF) is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers. The company also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics Inc., its joint venture with Amarantus Bioscience Holdings Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer's influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company's two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Breakthrough Diagnostics is developing the LymPro Test®, a blood test for diagnosing Alzheimer's disease. For more information, visit the company's website at www.todosmedical.com.
Ur-Energy (URG)
Ur-Energy (NYSE: URG) engages in uranium mining and recovery operations, with activities including acquisition, exploration, development and operation of uranium mineral properties in the U.S. The company operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming. Ur-Energy has produced, packaged and shipped more than 2 million pounds from Lost Creek since the commencement of operations. The company's newest project, Shirley Basin, is one of the Pathfinder Mines assets acquired in 2013. Baseline studies necessary for permitting and licensing of the project are complete, the WDEQ application for permit to mine has been submitted, and work on other permits is underway. For more information, visit the company's website at www.ur-energy.com.
VolitionRx Ltd. (VNRX)
VolitionRx (NYSE: VNRX) is a multi-national life sciences company focused on developing simple and easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Volition intends to expand the application of its technology beyond cancer by exploring other disease applications. For more information, visit the company's website at www.volitionrx.com.
WidePoint Corp. (WYY)
WidePoint (NYSE: WYY) delivers secure, cloud-based, enterprise-wide information technology-based solutions that can enable commercial enterprises and government agencies to deploy fully compliant IT services in accordance with government-mandated regulations and advanced system requirements. The company offers unique solutions in certificate-based security solutions, wireless telecommunication expense management systems, and associated consulting services. WidePoint's diverse portfolio of clients includes global and international organizations across a multitude of industries. For more information, visit the company's website at www.widepoint.com.
Zynerba Pharmaceuticals Inc. (ZYNE)
Zynerba Pharmaceuticals (NYSE: ZYNE) is the leader in pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, Autism Spectrum Disorder, 22q11.2 Deletion Syndrome (22q), and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). To meet these unmet medical needs, Zynerba is developing the next-generation transdermal cannabinoid therapeutics to improve the lives of patients. For more information, visit the company's website at www.zynerba.com.
